Company profile · free preview
Genmab
GMAB · NASDAQ · Healthcare · Updated 11/12/2026
Five-year financials
| Fiscal year |
|---|
| Revenue |
| Net income |
| Diluted EPS |
| Operating cash flow |
| Free cash flow |
| Cash |
| Total debt |
Financials are being prepared.
Want the story behind these numbers? Ask Osiris anything about Genmab's filings — free.
Create free accountGenmab return on capital (fiscal 2025)
ROIC
10.1%
Return on capital
12.2%
Return on equity
17.5%
Return on assets
10.0%
Gross margin
93.6%
Operating margin
33.6%
Net debt / EBITDA
3.13x
SEC filings
No filings stored yet.
Ask anything about Genmab's filings
"What changed since last year?" "Where is the cash going?" Get answers drawn straight from the filings.
Start researching freeGenmab research
Compare GMAB head-to-head
More Healthcare companies
Moderna MRNAEli Lilly LLYMerck MRKUnitedHealth Group UNHJohnson & Johnson JNJAbbott Laboratories ABTAmgen AMGNHims & Hers Health HIMSAbbVie ABBVThermo Fisher Scientific TMOTwist Bioscience TWSTPDS Biotechnology Corporation PDSBGE HealthCare GEHCRevolution Medicines, Inc. RVMDNovartis ANanoViricides, Inc. NNVCNektar Therapeutics NKTRRevvity, Inc. RVTYRapport Therapeutics RAPPViking Therapeutics VKTXPepGen Inc. PEPGTeva Pharmaceutical Industries Limited TEVACVS Health Corp. CVSTenon Medical, Inc. TNON